Use of Anti-Parafibromin Antibodies to Diagnose Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT) and Parathyroid Cancer
Description of Invention:
This technology relates to methods of diagnosing cancer using antibodies that specifically bind to parafibromin. Parafibromin appears to be a tumor suppressor. Mutations in the coding sequence, specifically truncations or deletions, might be indicative of cancer or increased susceptibility to cancer. Antibodies targeting this tumor suppressor protein might have utility as a cancer diagnostic or prognostic, either alone, or as part of a kit.
Inventors: William F. Simonds (NIDDK) Jian-hua Zhang (NIDDK) Geoffrey Woodard (NIDDK)
Patent Status:
DHHS Reference No. E-032-2004/0 --
U.S. Provisional Application No. 60/531,875 filed 22 Dec 2003
PCT Application No. PCT/US2004/43512 filed 22 Dec 2004, which published as WO 2005/064346 on 14 Jul 2005
Relevant Publication: GE Woodard et al. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene. 2005 Feb 10;24(7):1272-1276. [PubMed abs]
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-DNA Based Cancer -Diagnostics-In Vivo-Other Cancer -Diagnostics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
